A cheaper domestic option could change that calculation.
In Brazil, the expiration of a pharmaceutical patent has opened a door long closed to millions: a domestically produced version of semaglutida, the widely sought obesity medication, will reach pharmacy shelves on June 15 at nearly half the price of its imported counterpart. The company EMS, by pricing its pen at R$452 rather than the permitted ceiling of R$800, is doing more than competing in a market — it is quietly reshaping the conditions under which public health inclusion becomes thinkable. When cost is the wall, a lower price is not merely a commercial decision; it is a social one.
- Semaglutida has been one of Brazil's most desired yet least accessible medications, with monthly costs pushing R$1,000 and keeping the drug out of reach for the vast majority of patients.
- Previous efforts to include the medication in the public health system stalled entirely over price, leaving millions with obesity without a subsidized treatment pathway.
- EMS's launch at R$452 — 30% below the imported Ozempic and Wegovy — signals that domestic competition is now actively undercutting the market rather than simply matching it.
- Seventeen other Brazilian manufacturers still have regulatory applications pending, meaning the price pressure on this drug class is likely to intensify well beyond this first move.
- The immediate landing point is concrete: starting June 15, Brazilians will pay significantly less for semaglutida, and the conversation about SUS inclusion may finally have the numbers it needs to move forward.
A Brazilian pharmaceutical company will begin selling the country's first domestically manufactured semaglutida pen on June 15, priced at R$452 — roughly 30 percent below the imported versions that have dominated the market. The announcement was made at a closed industry event, and it carries weight beyond the commercial: semaglutida has become one of Brazil's most sought-after medications, yet at around R$1,000 per month, it has remained inaccessible to most people who need it.
EMS, the company behind the new version, received regulatory clearance to price its product at the same ceiling set for Novo Nordisk's Ozempic and Wegovy — approximately R$800 per unit. Instead, it chose to launch well below that threshold. The pricing follows a tiered structure: R$452 for the first three months of treatment, rising modestly to R$498 from the fourth month onward. A two-pen bundle has also been proposed, though without a confirmed release date.
The patent expiration that made this possible has already shifted the broader market. Novo Nordisk lowered its own prices in anticipation of domestic competition, and at least seventeen other Brazilian manufacturers have filed regulatory applications. That pipeline suggests further price reductions are likely as the market matures.
The deeper significance lies in what cheaper access might unlock. Inclusion of semaglutida in Brazil's public health system was previously blocked primarily by cost. With that barrier now substantially lower, those conversations may resume — and this time, the arithmetic may finally work in patients' favor.
A Brazilian pharmaceutical company announced this week that its domestically manufactured semaglutida pen will arrive in pharmacies starting June 15, undercutting the price of imported versions by roughly a third. The announcement came during a closed-door event for industry professionals and physicians, marking the first time a Brazilian-made version of the obesity medication has reached regulatory approval since the original patent expired.
The timing matters. Semaglutida has become one of the most sought-after drugs in Brazil, but at around R$1,000 per month, it remains out of reach for most people. The medication has been discussed for inclusion in the country's public health system, but those conversations stalled precisely because of the cost. A cheaper domestic option could change that calculation.
EMS, the company behind this new version, received regulatory clearance from Brazil's health agency to price its pen at the same ceiling the agency had set for Novo Nordisk's imported Ozempic and Wegovy products—roughly R$800 per unit. But EMS signaled from the start that it would undercut that price substantially. The company is launching at R$452 per pen, a 30 percent reduction from what patients have been paying for the imported drug. The pricing strategy reflects broader market dynamics: after the patent fell, Novo Nordisk itself lowered prices to stay competitive as domestic manufacturers began filing applications. By early this year, at least seventeen different companies had pending requests with the regulatory agency.
The company's pricing structure includes a tiered approach. For the first three months of treatment, patients will pay the R$452 price point. Beginning in the fourth month, the cost rises slightly to R$498 per pen. Both versions arrive on June 15. EMS has also proposed a bundle package—two pens containing 1.0 milligram doses each for R$896—though that option does not yet have a confirmed launch date.
What happens next will likely determine whether semaglutida finally enters the public health system. The lower price removes the primary obstacle that blocked previous inclusion discussions. With seventeen other domestic applications still under review at the regulatory agency, competition will only intensify, potentially driving prices down further. For now, the immediate effect is clear: Brazilians seeking obesity treatment will have a significantly cheaper option than they did a month ago.
Citas Notables
EMS signaled from the start that it would undercut the regulatory ceiling price substantially— Company strategy announcement
La Conversación del Hearth Otra perspectiva de la historia
Why did the patent expiration matter so much here? Couldn't domestic manufacturers have entered the market before?
No—the patent was a legal wall. Once it fell, the door opened. But the real shift is that now multiple companies can compete, and competition forces prices down. That's what we're seeing.
So Novo Nordisk lowered its own prices after the patent expired?
Yes, exactly. They had to. If they didn't, they'd lose market share to cheaper domestic versions. It's a rational response to losing monopoly protection.
The public health system rejected it before because of cost. Does R$452 change that conversation?
It should. The cost was the stated reason for rejection. If the price drops by a third, the math becomes different for whoever decides whether to include it in SUS.
But there are seventeen other applications pending. Won't those drive the price down even more?
Almost certainly. Each new competitor will try to undercut the last one. We're probably not at the floor yet.
What about people who can't afford even R$452?
That's the question the public health system would need to answer. If SUS includes it, cost becomes irrelevant for those patients. If it doesn't, R$452 is still cheaper than R$1,000, but still out of reach for many.